Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Targeting Histone Deacetylases in Idiopathic Pulmonary Fibrosis: A Future Therapeutic Option

12 May 2022

Abstract excerpt

Idiopathic pulmonary fibrosis (IPF) is a progressive and fatal lung disease with limited therapeutic options, and there is a huge unmet need for new therapies. A growing body of evidence suggests that the histone deacetylase (HDAC) family of transcriptional corepressors has emerged as crucial mediators of IPF pathogenesis. HDACs deacetylate histones and result in chromatin condensation and epigenetic repression...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
Share to Peptidase Inhibition and Analysis

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 35626663
DOI: 10.3390/cells11101626

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Targeting Histone Deacetylases in Idiopathic Pulmonary Fibrosis: A Future Therapeutic OptionPMID 35626663Read ↗

Histone deacetylases: potential therapeutic targets for idiopathic pulmonary fibrosisSemantic proximity Read ↗

Specific epigenetic regulators serve as potential therapeutic targets in idiopathic pulmonary fibrosisSemantic proximity Read ↗

HDAC inhibitors: Targets for tumor therapy, immune modulation and lung diseasesSemantic proximity Read ↗

Targeting Transcription Factor Lysine Acetylation in Inflammatory Airway DiseasesSemantic proximity Read ↗

The role of histone deacetylases in inflammatory respiratory diseases: an updateSemantic proximity Read ↗

Histone Deacetylase (HDAC) Inhibitors as a Novel Therapeutic Option Against Fibrotic and Inflammatory DiseasesSemantic proximity Read ↗

Targeting histone deacetylases for the treatment of cancer and inflammatory diseasesSemantic proximity Read ↗

Isoform-specific characterization of class I histone deacetylases and their therapeutic modulation in pulmonary hypertensionSemantic proximity Read ↗

The Role of Histone Deacetylases in Acute Lung Injury—Friend or FoeSemantic proximity Read ↗

Function of Histone Deacetylase Inhibitors in InflammationSemantic proximity Read ↗

Advances of HDAC inhibitors in tumor therapy: potential applications through immune modulationSemantic proximity Read ↗

The histone deacetylase inhibitor, romidepsin, as a potential treatment for pulmonary fibrosisSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.